|
Originally published In Press as doi:10.1074/jbc.M003206200 on June 26, 2000
J. Biol. Chem., Vol. 275, Issue 36, 27615-27626, September 8, 2000
Activation of Extracellular-regulated Kinase Pathways in
Ovarian Granulosa Cells by the Novel Growth Factor Type 1 Follicle-stimulating Hormone Receptor
ROLE IN HORMONE SIGNALING AND CELL PROLIFERATION*
Poda Suresh
Babu ,
Hanumanthappa
Krishnamurthy ,
P. Jorge
Chedrese§, and
M. Ram
Sairam ¶
From the Molecular Reproduction Research Laboratory,
Clinical Research Institute of Montreal, Montreal, Québec H2W
1R7, Canada and the § Department of Obstetrics, Gynecology
and Reproductive Sciences, University of Saskatchewan,
Saskatoon S7N 0W8, Canada
Received for publication, April 14, 2000, and in revised form, May 30, 2000
 |
ABSTRACT |
Follicle-stimulating hormone (FSH) regulated
growth and function of the ovarian follicle was previously thought to
be mediated solely through activation of Gs-coupled
receptors. In this study, we show for the first time that this function
is predominantly mediated through the alternatively spliced and novel
growth factor type 1 receptor (oFSH-R3) that is also present in the
ovary. Immortalized granulosa cells lacking endogenous FSH receptors,
when transfected with either oFSH-R3 cDNA (JC-R3) or the
Gs-coupled oFSH-R1 (JC-R1), expressed the corresponding
glycosylated receptor. In JC-R3 or JC-R1 cells labeled with
bromodeoxyuridine or [3H]thymidine, FSH stimulated
the cells to progress through S-phase and divide. The growth promoting
effect of recombinant FSH in JC-R3 cells was preceded by the rapid
activation of ERK1 and ERK2. This effect was hormone-specific and
transient. In JC-R3 cells inhibitors like calphostin C,
PD98059, Ag 18, or calcium chelators EGTA or
1,2-bis(O-aminophenoxy)ethane-N,N,N',N'-tetraacetic
acid/AM inhibited both mitogen-activated protein kinase activation and bromodeoxyuridine incorporation. FSH induced phosphorylation of the
FSH-R3 receptor was blocked by pretreating cells with calphostin C. There was no cAMP induction by FSH in JC-R3 cells. The cAMP independent
growth promoting effect of FSH is mediated by activation of
Ca2+ and mitogen-activated protein
kinase-dependent pathways. Thus, alternative splicing of a
G-protein coupled receptor creates the expression of a novel receptor
motif that can mediate a widely recognized function of the glycoprotein hormone.
 |
INTRODUCTION |
The ovarian follicle is among the most prolific of normal tissues
undergoing rapid cellular proliferation and differentiation to
accommodate the development and maturation of the ovum that is vital
for propagation of the species. Two dimeric pituitary gonadotropins,
follicle-stimulating hormone or follitropin
(FSH)1 and luteinizing
hormone or lutropin (LH) that belong to the complex glycoprotein
hormone family are critically involved in the mechanisms regulating
follicle status and development. The actions of gonadotropic hormones
are mediated by binding to high affinity receptors present on plasma
membranes of target gonadal cells. FSH regulates a large number of
genes encoding nuclear, cytoplasmic, membrane associated (1), and
secreted proteins (2). The full-length FSH receptor (hereafter called
FSH-R1) belongs to a superfamily of G-protein coupled receptors, which
interact with intracellular effector system through 7-transmembrane
domains (3-5). This FSH-R1 receptor like LH and TSH
(thyroid-stimulating hormone, thyrotropin) receptors has a large
extracellular (EC) amino-terminal domain comprised of more than 300 amino acid residues. The EC domains of these receptors are encoded by
multiple exons and contain leucine-rich repeat sequences that are
thought to be important for ligand binding. According to present
evidence, the FSH receptor is coded by a single large gene (80-100
kilobases), in various species (3, 6). Alternative pre-mRNA
splicing is a widespread theme for gene regulation and for generating
isoform variants as this mechanism will ensure molecular diversity for
cellular regulation in instances where only one gene exists (7). There
are many reports on the identification of various alternatively spliced
transcripts for most glycoprotein hormone receptors including that of
FSH in the ovary and testis, the two exclusive targets of the hormone
action (4, 5, 8, 9). In our previous investigations, we have reported
the cloning of several alternatively spliced FSH receptors displaying
different structural motifs including a dominant negative receptor
(designated FSH-R2) (5, 11), a growth factor type 1 receptor (called
FSH-R3) (10, 12), and a potential soluble form (called FSH-R4) (13,
14). The biochemical characteristics of the ovine FSH-R3 receptor motif
(10) including the identification of protein expression in the ovary
and testes have been described (12).
Follicles in the ovary are either quiescent or committed to one of the
two developmental pathways: growth or atresia/apoptosis. Although most
of the growth in the follicles is attributed to the proliferation of
granulosa cells under the tropic influence of FSH, the molecular
mechanisms and the exact receptor motifs that participate in the
process are poorly understood. Recent evidence derived from the
generation of knockout mutants for the FSH- subunit (lacking the
hormone dimer) (15) and all forms of the FSH receptor (16) in the mouse
substantiate the importance of the hormone-receptor interaction in
follicular development. The presence of underdeveloped ovarian
follicles in our FSH-R knockout mouse suggests that FSH signaling is
critical in the final phases of follicular growth and maturation
(16).
Recent studies of numerous cells undergoing proliferation in response
to various extracellular signals have demonstrated the activation of
mitogen-activated protein kinases (MAP kinases) or
extracellular-regulated kinases (ERK). The ERK cascade consists of
3-kinase modules that include a MAPK which is activated by a MAPK/ERK
kinase (MEK), which is in turn activated by another MEK kinase (MEKK)
(17). Multiple mammalian MAPK pathways have been identified, of which
the ERK cascade is the best characterized. It consists of Raf isoforms,
MEK1/2 and ERK1/ERK2 and is regulated by Ras. In addition, it is also
known that proto-oncogenes, the normal cell progenitors of oncogenes
may regulate the growth and differentiation of normal cells.
Accordingly, a number of observations like the transient increase in
c-fos, c-myc expression, and MAP kinase
activation were reported in primary granulosa cell cultures in response
to FSH (18-20) and some of the actions are apparently mediated by cAMP
independent pathways (19, 20). This raises the critical question
whether all FSH actions on target cells are mediated by one type of
receptor (R1), the heptahelical transmembrane form that is coupled to
the activation of adenylyl cyclase producing cyclic AMP as the second
messenger? As the FSH receptor gene undergoes extensive alternative
splicing (3, 6) and most of the earlier observations in literature are
made with primary cultures of target cells that may express
heterogeneous populations of FSH receptors, it is conceivable that
other FSH receptor motifs may be implicated in signaling events that
contribute to cell proliferation. In view of its novel structural
features, the alternatively spliced receptor 39-kDa FSH-R3 identified
in the developing ovary (12) that is distinctly different from R1
becomes a good candidate. Like other growth factor type I receptors,
the FSH-R3 has a single transmembrane domain and undergoes dimerization
in response to the action of FSH (10). We have also shown that this R3
type receptor but not the Gs-coupled R1 receptor mobilizes
Ca2+ influx into the cell through L-voltage
Ca2+ channels (21). The experiments presented herein were
designed to test for the potential role of this growth factor type I
receptor in FSH-mediated MAP kinase signaling in target granulosa cell proliferation. The availability of a granulosa cell line (JC-410) (22,
23) that lost innate expression of gonadotropin receptors during
spontaneous immortalization but retained its steroidogeneic capability
has provided us an ideal system to understand the role of the
alternatively spliced FSH receptor in hormone signaling. The results of
the current study provide the first direct evidence strongly
implicating a role for the novel growth factor type I receptor in
activating extracellular-regulated kinase pathways by mechanisms that
are independent of the cAMP pathway.
 |
MATERIALS AND METHODS |
Reagents--
Highly purified recombinant hormones rhFSH (AFP
8468A), rhCG (AFP8456A), and rhLH (1295 RL) were obtained from the
National Institutes of Health, Bethesda, MD. For iodination, highly
purified hFSH prepared in our laboratory was used. Anti-rFSHR (W970) a polyclonal antibody against rFSHR (sequence 150-183) was kindly provided by J. Dias (State of New York, Department of Health, New
York). Anti-oFSHR antibody (J25) is a rabbit polyclonal antibody obtained by immunizing Escherichia coli expressed R4-type
oFSHR (24). Other antibodies used in this study are P44/42 MAP kinase, phosphospecific P44/42 MAP kinase, Akt, and phosphospecific Akt (New
England Biolabs), anti-BrdUrd antibody (DaKo Diagnostic, Ontario),
anti-glucose-6-phosphate dehydrogenase antibody (Sigma). Ag 18 was
kindly furnished by Dr. A. Levitzki of Jerusalem, Israel. All other
inhibitors used in this study were purchased from Calbiochem.
Cell Culture, Transfections, and Signaling--
The immortalized
pig granulosa cells (JC-410) were handled as described earlier (22),
except that DMEM/F-12 medium was used for cell culture instead of
M-199. pcDNA1 Neo vector (Invitrogen) containing the complete
coding sequence for oFSH-R1 of 678 residues (11) and oFSH-R3 of 242 residues (10) of the respective mature proteins was transfected into
JC-410 cells. For making stable cell lines the calcium precipitate
protocol was used. Densely growing foci of transformed cells were
visualized, selected for 8 weeks using G418 (Life Technologies, Inc.,
Mississauga, ON; 400 µg/ml) and expanded into cell lines. Initial
screening for cells expressing the oFSH-R3 protein was performed by
125I-hFSH binding and responsive cells were further used
for signaling studies in serum-deprived medium in the presence of
stimulators or inhibitors as described in the individual experiments
outlined below.
Ligand Binding Assay--
This was performed according to
published protocols (10, 11). Highly purified hFSH was labeled with
125I by the lactoperoxidase method (specific activity
100,000 cpm/ng) and incubated with granulosa cells expressing FSH-R3 or
R1 or the vector control. The membranes were incubated for 12 h at
25 °C with 100,000 cpm/ml 125I-FSH in presence or
absence of excess unlabeled oFSH. Specific binding was determined in
presence of 1 µg of unlabeled oFSH. The number of receptor molecules
present in either JC-R3 or JC-R1 cells was determined as described
earlier (10).
Genomic DNA and Reverese Transcriptase Polymerase Chain
Reaction--
Cells were washed with PBS and lysed in lysis buffer
(0.2 mM Tris, pH 8.0, 0.1 M EDTA, 1% SDS, and
100 µg/ml proteinase K) and digested for 3 h at 50 °C with
gentle shaking. Salt concentration was adjusted to 0.2 M
NaCl and DNA was extracted using phenol-chloroform. PCR using genomic
DNA was performed with neomycin-specific primers: forward,
AAGGGACTGGCTGCTATTG (RS 003) and reverse, AGAAAAGCGGCCATTTTC (RS 004)
to amplify a 348-bp fragment.
RNA from cells expressing FSH-R3 or FSH-R1 and cells transfected with
pcDNA1 vector alone were extracted using midi-RNA isolation kit
(Ambion) and reverse transcribed using first strand synthesis kit
(Ambion). The cDNAs were used to amplify both oFSH-R3 and oFSH-R1
using specific primers SFR1 (ATGTGTTCTCCAACCTGCCCA) and TB21
(CTGACTCGAGCTAATTTGGATGCTGCTTGA) for an expected size of 517 bp for R3
and SFR1 and SFR11 (CATCATCTTCTGCCAAAGAGA) for R1 with an expected size
of 690 bp. The products were separated on 1.5% agarose gel and stained
with ethidium bromide.
Cell Surface Expression of oFSH-R3 and oFSH-R1 in Granulosa Cells
by Immunocytometry--
The cells (1 × 106/ml)
transfected with/without FSH-R3 or FSH-R1 were harvested and fixed in
1% buffered paraformaldehyde (pH 7.4) for 30 min at 4 °C. The cells
were washed thrice with 3 ml of staining buffer (PBS containing 1%
bovine serum albumin) and resuspended in 100 µl of staining buffer
containing the FSH-R antisera (1:100) raised in rabbits and incubated
at room temperature for 1 h. They were again washed and incubated
with 100 µl of staining buffer containing fluorosceinated goat
anti-rabbit IgG (1:50 dilution) in the dark for 30 min at room
temperature. After one more final wash they were resuspended in 1 ml of
staining buffer. The green fluorescence intensity of cells was measured
in a Coulter flow cytometer at 530 nm. Control cells were processed in
the same manner excluding the primary antibody. The antibodies used
were characterized previously and shown to react with FSH receptor in
cells or gonadal tissues (12, 24, 25).
Deglycosylation of oFSH-R3 in JC-R3 Cells--
The cells were
scraped in cold PBS and collected after centrifugation at 800 × g for 10 min at 4 °C. They were suspended in lysis buffer
and left on ice for 30 min to solubilize membrane proteins. The
solubilized receptor was deglycosylated using N-glycosidase F (Roche Molecular Biochemicals), which cleaves all N-linked
glycomoieties of the FSH receptor (26). Approximately 200 µg of
membrane protein was suspended in 0.1 M Tris-HCl buffer (pH
7.4) with 0.1 mM phenylmethylsulfonyl fluoride and
incubated with 50 units/ml N-glycosidase F. After incubation
for 4 h at 30 °C, 100 µg of equivalent protein was reduced in
1 × SDS sample buffer and subjected to SDS-PAGE followed by
immunoblotting using the FSH-R3-specific peptide antibody (12).
Western Blot Analysis--
Granulosa cells expressing the cloned
oFSH-R3 or oFSH-R1 were stimulated in serum-free medium as described in
the figure legends. In preliminary studies, we used natural and highly
purified hFSH and hLH or hCG prepared in our laboratory. In subsequent
experiments all data reported herein were derived from the use of
recombinant human glycoprotein hormones (see "Methods").
Cells collected by scraping in cold PBS were washed and homogenized in
lysis buffer (20 mM Tris-HCl, pH 7.4, 150 mM
NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100,
2.5 mM sodium pyrophosphate, 1 mM
Na3VO4, and 0.1 mM
phenylmethylsulfonyl fluoride). Protein content in the samples was
estimated by the Bio-Rad protein assay. For verifying the expression of
FSH-R3 ~100 µg of protein was used whereas for MAP kinases 5 µg
of total solubilized protein was adequate. Proteins were separated on
10% SDS-PAGE minigel and transferred onto polyvinylidene difluoride
(DuPont) membranes. After blocking nonspecific sites, membranes were
incubated with anti-MAP kinase (1:1000), phospho-MAP kinase (1:1000),
oFSH-R3 IgG (1:2000), or FSHR Ab (1:2000) in TBS containing 1% (w/v)
skim milk powder and 0.05% Tween 20 for 12 h at 4 °C. The
washed blots were incubated with goat anti-rabbit IgG conjugated to
horseradish peroxidase (Sigma) at 1:3000 dilution. Bound antibody was
visualized using the Luminol (Roche Molecular Biochemicals)
chemiluminescent detection system.
Quantification of Granulosa Cell Proliferation by BrdUrd
Incorporation and Dual Parameter Flow Cytometry--
The
quantification of BrdUrd-positive cells by flow cytometry can be
considered as a measure of actively dividing S-phase cells (27).
Quantification of BrdUrd-labeled cells was done according to the
procedure described earlier (28). Granulosa cells transfected
with/without FSH-R3 or FSH-R1 receptor were growth arrested by serum
starvation for 16-24 h and treated with various concentrations of
human recombinant FSH and 50 µM BrdUrd. After 1 h of
incubation at 37 °C, the cells were washed three times with
Dulbecco's phosphate-buffered saline (Ca2+ and
Mg2+-free) and fixed in 70% chilled ethanol at a
concentration of 1 × 106 per ml. An aliquot of
ethanol-fixed cells (2 × 106) was washed, pepsinized,
acid denatured, and incubated with 200 µl of a monoclonal antibody
against BrdUrd at 1:40 dilution for 1 h in dark. The cells were
washed and incubated with 200 µl of fluorescein
isothiocyanate-conjugated goat anti-mouse IgG (Sigma) at 1:10 dilution
for 30 min in dark and cells were counterstained with propidium iodide
staining solution containing 100 µg/ml DNase-free RNase. Control
cells were processed similarly without incubating with BrdUrd. The
intensity of green fluorescence of fluorescein isothiocyanate staining
and red fluorescence of propidium iodide-stained cells were
measured at 530 and 620 nm, respectively, in a Coulter Flow Cytometer.
Measurement of [3H]Thymidine
Incorporation--
Granulosa cells (JC-R3, JC-R1, or JC-Vector) were
plated at a density of 2.5 × 104 cm2 in
24-well tissue culture plates and grown for 2 days without a medium
change. They were rinsed once with serum-free DMEM and serum starved
for 16 h by incubating with DMEM. The medium was changed to DMEM
containing varying concentrations of rFSH plus 1 µCi/well of
[3H]thymidine (specific activity 79 Ci/mmol). The cells
were incubated at 37 °C for 24 h and the amount of
[3H]thymidine incorporated into DNA was determined as
described previously (10).
Phosphorylation of Intact JC-R3 Cells and
Immunoprecipitation--
JC-R3 cells plated in 100-mm dishes were
biosynthetically labeled in phosphate-free DMEM medium with 100 µci/ml [32P]orthophosphate for 3 h at 37 °C
under 5% CO2 as described by others (29) and stimulated
for another 30 min with 10 ng/ml rFSH. The plates were placed on ice
and cells were scraped into cold buffer (0.15 M NaCl, 20 mM HEPES, pH 7.4, containing a mixture of protease
inhibitors and 0.5% Nonidet P-40). Cells were solubilized on ice for
30 min and centrifuged at 100,000 × g for 30 min. The soluble receptor in the supernatant was immunoprecipitated using anti-FSH R3 IgG antibody and resolved on SDS-PAGE in the presence of
thiol reducing agents. Autoradiographs of dried gels were obtained using intensifying screen.
Steroid Hormone (Estradiol), cAMP Production, and Protein
Assays--
Stable granulosa cells expressing oFSH-R3 (JC-R3) or
oFSH-R1 (JC-R1) were evaluated for their capacity to stimulate
estradiol production. Estradiol-17 was estimated by radioimmunoassay
in 200 µl of culture medium, as described previously in the presence or absence of 0.1 µl of androstenedione (22). For cAMP estimation, 2'-O-monosuccinyl adenosine 3',5'-cyclic monophosphate
methyl ester was labeled with Na125I using chloramine T. Cells were cultured in DMEM/F-12 medium containing 0.1 mM
3-isobutyl-1-methylxanthine (Sigma). The cAMP produced was measured
using the double antibody precipitation method (5) and expressed as
picomole/µg of protein. Cells were washed twice with PBS and
solubilized in cell lysis buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, and
0.1 mM phenylmethylsulfonyl fluoride) and cellular protein content was determined with Bio-Rad protein assay kit.
Statistical Analysis--
All data are expressed as mean ± S.E. and analyzed by one-way ANOVA. A value of p < 0.05 was considered to be statistically significant.
 |
RESULTS |
Establishment of Stable Granulosa Cells Expressing Alternatively
Spliced Growth Factor Type 1 Receptor (JC-R3)--
The role of
alternatively spliced FSH-R3 signaling was evaluated in granulosa cell
line (JC-410) which had lost the responsiveness to gonadotropins during
spontaneous immortalization (22), but retained expression of several
genes required for steroidogenesis. The retention of these phenotypic
features is critical in examining all phases of hormone action.
Accordingly this ovarian cell line provides a convenient in
vitro model for creating responsive target cells with discrete
receptor motifs. Following transfection of granulosa cells with the
oFSH-R3 or oFSH-R1 construct in the pcDNA1 Neo vector, successful
transfectants were identified and selected by their resistance to G418
(400 µg/ml) for 8 weeks. The stable cell lines are, hereafter named
JC-R3 and JC-R1, respectively. Further screening of these stable cell
lines was done by PCR to confirm the expression of neomycin. Neomycin
(348 bp) was amplified only in the cell lines transfected with FSH-R3
or FSH-R1 (Fig. 1A). The
expression of oFSH-R3 and oFSH-R1 was also confirmed in these cells by
RT-PCR using primers specific for FSH-R3 and FSH-R1. A 517-bp product
specific to FSH-R3 was amplified only in FSH-R3 transfected cell lines
(Fig. 1A) but not with vector alone. Similarly a 690-bp
product, which spans between exon 3 and 10 for FSH-R1, was expressed
only in JC-R1 cells. These results not only showed the faithful
expression of R3 type receptor in the JC-R3 cell lines and R1 in JC-R1
cells but also confirmed the absence of any endogenous FSH receptors in
the vector-transfected cells.

View larger version (49K):
[in this window]
[in a new window]
|
Fig. 1.
Expression of the oFSH-R3, oFSH-R1 receptors
in stably transfected granulosa cells. Panel A,
verification by PCR of neomycin and receptors in transfected cells.
Genomic DNA was extracted from granulosa cells by phenol-chloroform
method and subjected to PCR (95 °C for 4 min denaturation, 94 °C
45 s, 54 °C 45 s, and 72 °C 1.5 min for 30 cycles with
final extension at 72 °C of 10 min) using primers specific for
neomycin SC 004 and SC 003 (fragment size 348 bp). To verify R3 and R1
receptor expression, RT-PCR was done on total RNA isolated from vector,
oFSH-R3, and oFSH-R1 cDNA transfected granulosa cells as described
under "Materials and Methods" and subjected to reverse
transcription using Molony murine leukemic virus-reverse transcriptase
(Ambion) for 1 h at 42 °C. The cDNA was further subjected
to PCR (95 °C for 4 min denaturation, 94 °C 1 min, 55 °C 1.5 min, 72 °C 1.5 min for 30 cycles and final extension at 72 °C for
10 min) using R3- and R1-specific primers. The PCR products separated
on 1.5% agarose gel are shown along with the positions of known DNA
markers on the left. Only JC-R3 and JC-R1 not
Vector-transfected cells show specific expression of FSH-R3 (517 bp)
and FSH-R1 (690 bp), respectively. Panel B shows hormone
binding in granulosa cells: membranes were prepared from cells as
described under "Materials and Methods" for measuring radioligand
(125I-hFSH) binding during 12 h at 25 °C.
Equivalent amounts of JC-vector, JC-R3, and JC-R1 were incubated in the
presence or absence of 1 µg of unlabeled purified hormone (oFSH)
along with the labeled hormone. To determine hormonal specificity of
binding, purified oLH was used as a competitor instead of oFSH with
JC-R3 membranes. Note that specific binding is observed only with JC-R3
and JC-R1 cells. Panel C, analysis of cell-surface
expression of oFSH-R3 by cytofluorimetry: cells were prepared and
analyzed with the control and experimental antibodies as described
under "Materials and Methods." Histograms are presented showing the
binding of two polyclonal antibodies against FSH-R (W970 and J25) to
granulosa cells expressing receptors (upper panel, JC-R3
cells). The panel shows the reaction of S.AbFITC (solid
line) and normal rabbit serum (bold solid line) as
controls. Specific antibody binding indicated by the right shift are
shown by J25 (dashed line) and W970 (fainter dotted
line). J25 is an antibody to the recombinant oFSH receptor protein
and W970 is a rat FSH-R peptide antibody (see "Materials and
Methods"). The lower panel represents the cell surface
expression of oFSH-R1 in JC-R1 cells.
|
|
Radioligand Binding Assay and Cell Surface Expression--
The
cell surface expression and 125I-hFSH binding to JC-R3 or
JC-R1 membranes are shown in Fig. 1B. The binding of
125I-hFSH was effectively competed by unlabeled FSH but not
the structural homologous hormone LH. In the same experiment granulosa
cells transfected with vector alone showed no specific binding of
labeled FSH. Previously, we have reported that HEK 293 cells expressing the same FSH-R3 or FSH-R1 cDNA show high affinity binding
(Kd = 0.17- 0.27 nM) to labeled FSH (10)
similar to receptors in the target tissue (Kd = 0.66 nM). From the binding data in this study the number of
receptor molecules present in the JC-R3 and JC-R1 were estimated to be
approximately equal (~2000 R/cell). Taken together these data confirm
that the first 8 exons, which account for about 61% of the
extracellular domain of the R1 receptor, is sufficient for efficient
hormone binding when it is combined with a single transmembrane protein
segment that allows cell surface expression (10) (see below).
Analysis of intact JC-R3 or JC-R1 cells with selected and previously
characterized antibodies using flow cytometry also showed that both
these receptors were present on the cell surface. The two antibodies
used in this study are rabbit polyclonal antibodies prepared against
segments of the extracellular domain of the FSH receptor. The
polyclonal J25 reacts with determinants within the exon 1-4 of oFSH-R
and W970 is a peptide antibody to rat FSH-R-(150-183). Both antibodies
have been used earlier to detect FSHRs in the target and transfected
cells (25, 30). Fig. 1C shows the histograms depicting right
shift of antibody bound to cells expressing FSH-R3 (upper
panel) and FSH-R1 (lower panel), whereas these
antibodies did not show any specific binding with JC-410 cells
transfected with vector alone (data not shown). Thus, we were able to
demonstrate the specificity of the system by detecting the capability
of JC-R3 cells for expression of R3 protein on the cell surface and R1 protein in JC-R1 cells.
Western blotting of extracts of membranes solubilized from JC-R3, using
R3-specific peptide antibody, detected a band of approximately 39 kDa
(Fig. 2A). In previous studies
we had used this antibody to show the expression of FSH-R3 both in the
sheep ovarian and testicular membranes (12). The apparent increase in
the molecular weight that is different from the value predicted from
the cDNA sequence (12) is suggestive of the covalent modification
of one or both of the two potential N-glycosylation sites in
FSH-R3. Previously published data suggest that in both FSH-R and LH/hCG receptors, glycosylation patterns influence the migration in SDS-PAGE and these receptors are sensitive to N-glycosidase F
treatment (26, 31, 32). Accordingly, we tested for the presence of glycosylation sites (at Asn-174 and -182) of the receptor in
transfected cells as described earlier with slight modifications (33).
Digestion of soluble cell extracts expressing FSH-R3 with
N-glycosidase F led to a decrease in the molecular
mass by ~8-10 kDa, which was clearly evident by the downward
shift in protein mobility. Thus, it appears that the
N-linked oligosacharides of expressed R3 receptor are
accessible to the action of N-glycosidase F. The results
suggest that recombinantly expressed FSH-R3 in the granulosa cells is a
glycoprotein that is N-glycosylated at both sites as predicted by its cDNA structure.

View larger version (44K):
[in this window]
[in a new window]
|
Fig. 2.
Characterization of oFSH-R3 expression by
immunoblotting and enzymatic deglycosylation. Granulosa cells
expressing FSH-R3 (JC-R3) or FSH-R1 (JC-R1) and without (JC-Vector)
were solubilized using Nonidet P-40 for immunoblotting. Extracts of
JC-R3 cells were incubated in the absence or presence of N-
glylcosidase F before analysis. For examination of receptor in the
mouse, extracts prepared both from FSH receptor knockout mouse FORKO
( / ) and wild-type mouse (+/+) ovarian membranes were utilized. An
equal amount of protein (100 µg) was loaded to each well and
subjected to SDS-PAGE, followed by transfer to polyvinylidene
difluoride membrane. The blot was incubated with anti-oFSH-R3 peptide
IgG (1:2000) in A, or FSH-R antibody (J25) in B,
and bound antibody detected using peroxidase-conjugated anti-rabbit IgG
antibody and a chemiluminescence detection system. The respective lanes
are identified with the estimated Mr shown on
the right side. Note that the R3 protein band is not
detected in the ovary of FSH receptor knockout mouse. The blot (Fig.
2A) was stripped and reprobed to check for normalization and
internal control (glyceraldehyde-3-phosphate dehydrogenase
(GAPDH)) for each sample. In B the extracellular
domain antibody detects both R1 and R3 in the +/+ but not ( / mouse
ovary. Respective receptor bands are observed in JC-R3 and JC-R1
cells.
|
|
As a further confirmation of specificity, we have verified by Western
immunoblotting the soluble extracts of adult mouse ovarian tissues
using antibody directed against the COOH-terminal end of R3. The
immunoblot revealed a distinct band with the normal mouse ovary of a
size similar (39 kDa) to that of cells expressing this receptor (Fig.
2A). It may be noted that in the same blot the ovarian
extract of the FSH-R knockout ( / ) mouse does not show any
immunoreactivity indicating the specificity of the R3 peptide antibody
(12). The bottom panel of Fig. 2A shows the blot
probed with glyceraldehyde-3-phosphate dehydrogenase antibody revealing
approximately equal loading for all lanes. The immunoblot with both
mouse ovary extracts and cells expressing R1 and R3 treated with an
FSHR antibody (J25) which recognizes both forms of receptors is shown
in Fig. 2B. The expression of corresponding proteins in
respective transfected cells identifies bands of the correct size only
in extracts of +/+ mouse ovary. These data confirm for the first time
that a receptor equivalent to FSH-R3 is also present in the mouse ovary.
Cyclic AMP Production in JC-R3 and JC-R1 Cells--
As shown in
Fig. 3, when JC-R3 or JC-R1 and vector
control cells were stimulated with different concentrations of rFSH,
there was no accumulation of cyclic AMP in JC-R3 cells despite the
presence of the phosphodiesterase inhibitor. These results, verified
several times, suggest that the R3 receptor expressed in the granulosa cells is not coupled to the activation of cAMP unlike FSH-R1 type of
receptor. In JC-R1 cells expressing the Gs-coupled
receptor, cAMP increase was evident in the presence of 1 ng/ml FSH.
(Fig. 3). The latter is consistent with numerous reports showing that FSH-R1 in HEK 293 cells is efficiently coupled to this signaling pathway (3, 5, 11). Forskolin, a non-hormonal adenylyl cyclase
activator, promptly increased cAMP production in JC-R3 cells in a
concentration-dependent manner from 1 to 10 µM indicating that following FSH-R3 cDNA transfection
the G-protein coupled signaling apparatus is fully intact.

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 3.
cAMP production in JC-R3 and JC-R1
cells. Granulosa cells transfected with oFSH-R3 (JC-R3) or oFSH-R1
(JC-R1) and without receptor (JC-Vector) were cultured in serum-free
DMEM/F-12 medium. Cells were stimulated either with rFSH or different
concentrations of forskolin for 1 h at 37 °C in presence of 0.1 mM 3-isobutyl-1-methylxanthine. After 1 h the cAMP
produced in the cells was measured by radioimmunoassay using double
antibody binding method. Protein content in the lysates was determined
by Bio-Rad protein assay. Compared with the statistically significant
increase in cAMP at 1 ng/ml for JC-R1 there is no such effect for JC-R3
cells even at 1000 ng of FSH/ml. Stimulation by forskolin is shown only
for JC-R3 cells.
|
|
FSH-induced Phosphorylation--
The results presented in Fig.
4 show that cells expressing oFSH-R3
respond to rFSH (10 ng/ml) or phorbol 12-myristate 13-acetate (200 nM) with a 4-fold increase in receptor phosphorylation
compared with unstimulated cells. The FSH-induced phosphorylation was
partially blocked by pretreating the FSH-R3 expressing cells with PKC
inhibitor calphostin C, suggesting that FSH-R3 receptor phosphorylation is mediated by either PKC or one or more other kinases.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 4.
Phosphorylation of the oFSH-R3 in stably
transfected granulosa cells. The JC-R3 granulosa cells stably
expressing oFSH-R3 were biosynthetically prelabeled with
32P for 4 h and further incubated with or without 10 ng/ml rhFSH for 45 min as indicated. In some experiments, cells are
treated with either phorbol 12-myristate 13-acetate (PMA)
for 20 min or pretreated with PKC inhibitor calphostin C for 30 min
prior to FSH stimulation. Immunoprecipitates of FSH-R3 were prepared
using R3 specific antibody as described under "Materials and
Methods." The results presented at the bottom are
densitometric scan of representative autoradiographs obtained using
equal amount of protein used for immunoprecipitation. Lane
1, JC-vector; lanes 2-5, JC-R3 treated as shown.
|
|
Regulation of MAP Kinase Pathway in JC-R3 Cells--
The
regulation of MAP kinase pathway in JC-R3 cells was monitored by
measuring the total phosphorylation pattern and activation of two MAP
kinase isoforms, ERK1 and ERK2. Cells were maintained in serum-free
medium for 12 h to arrest growth and then stimulated with the
hormone. The cells were harvested at different time periods and
subjected to Western blot analysis using antibody that specifically recognizes the phosphorylated form of ERK1 and ERK2 (Fig.
5A). Remarkably, these
phosphorylated forms of ERK1 and ERK2 became quickly detectable within
5 min of hormone addition and reached maximum at 10 min and then
declined to almost basal level by 60 min. However, repeated experiments
confirmed that FSH is unable to activate other kinases including both
P38 and SAPK/JNK in JC-R3 cells (data not shown). This is probably
because these two pathways are primarily associated with cellular
stress responses, a signaling mechanism that may not be mediated by the
FSH-R3 in the granulosa cell. Fig. 5B shows the
concentration (FSH) dependent increase in ERK1 and ERK2 activation in
JC-R3 cells. It may be noted that a very low concentration of the
hormone FSH (0.1 ng/ml 3 × 10 12 M)
is sufficient to double ERK1 and ERK2 activation, and this effect is
enhanced with increasing FSH up to 100 ng/ml.

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 5.
Activation of MAP kinases (ERK1/ERK2) by FSH
in JC-R3 granulosa cells. Panel A, serum-starved cells were
stimulated with FSH as indicated. In some experiments, cells were
pretreated for 30 min to PD98059, calphostin C, and H89 at a concentration of
10 5 mol/liter before agonist (FSH) stimulation. Cells
were harvested in lysis buffer as described under "Materials and
Methods" and equal protein concentrations (5 µg) were analyzed by
Western blot using antiphospho-specific ERK (p44/42) antibody. The
intensity of the band in each lane demonstrates the degree of increase
in ERK (ERK1 + ERK2) phosphorylation in cells (ERK 1/2-P). The
middle section of this panel represents unphosphorylated MAP
kinase (ERK1/2) activities in the same blot. The lower
section summarizes the densitometric scanning of phosphorylated
MAP kinases. To get a better idea of the relative activation status,
respective lanes in each treatment were scanned by densitometry and the
data expressed as a ratio by dividing the intensity of ERK1/2-P in each
lane by the corresponding value for ERK 1/2. Panel B, for
examining hormone-dependent phospho-specific MAP kinase
(ERK1/ERK2) activation, the cells were stimulated for 10 min with
increasing concentrations of rhFSH (0.1, 1, 10, and 100 ng/ml,
respectively). Blots were probed as above in panel A. The
middle section represents MAP kinase (ERK1/2) expression in
the same blot. Bands were scanned by densitometry and relative
activation status was calculated as in Fig. 5A. Note that
activity is doubled at 0.1 ng FSH/ml (~3 × 10 12
M). Panel C, hormone (FSH) specific activation
of MAP kinase in JC-R3 cell lines: serum-starved cells, JC-410,
JC-vector, and JC-R3 cells, were stimulated with either rFSH or rhCG
(with different concentrations) as shown in the figure for 10 min. In
Ag18-treated cells, cells were pre-exposed at a concentration of
10 5 mol/liter for 30 min. The cells are lysed in lysis
buffer as described under "Materials and Methods" and equal amounts
of protein loaded on 10% SDS-PAGE and immunoblotted using
phospho-specific anti-ERK1/ERK2 MAP kinase antibody. Serum-treated
JC-R3 cells serve as a positive control for comparison. Note the lack
of activation by rhCG at any concentration. The lower
section shows the expression of MAP kinase in the same blot after
reprobing.
|
|
As it is known that PKCs are involved with activation of ERK MAP kinase
pathway, we studied the effect of both PKC inhibitor (calphostin C) and
MEK inhibitor (PD98059) on FSH action in JC-R3 cells (Fig.
5A). Pretreatment of cells either with PD98059 or calphostin
C at a concentration of 10 5 mol/liter for 30 min prior to
FSH stimulation blocked the activation of ERK1 and ERK2 indicating the
potential role of PKC pathways in the activation of MAP kinases.
However, as the compound H89, which is a PKA inhibitor did not produce
a comparable effect significant involvement of cAMP pathways in the
activation of MAP kinases is unlikely in JC-R3 cells. This result is in
agreement with the lack of cAMP production by FSH in JC-R3 cells (Fig.
3). The specificity of FSH induced activation of ERK1 and ERK2 in JC-R3
cells is supported by data shown in Fig. 5C. The JC-R3 cells
stimulated with 10% serum for 10 min served as positive control,
whereas the JC-410 or vector transfected cells stimulated under
identical conditions with FSH did not show any activation of ERK1 and
ERK2. Similarly the homologous hormone, rhCG, did not have any effect
on activation of MAP kinases in JC-R3 cells (Fig. 5C).
Compared with the 2-fold activation with 0.1 ng/ml FSH (Fig.
5B), rhCG at 100 ng/ml was without effect. Results were
similar using highly purified natural hCG (data not shown). In light of
these novel observations, we compared the effects of the hormone in
JC-R1 cells designed to express the Gs-coupled receptor. It
was already shown (Fig. 3) that FSH activates adenylyl cyclase promptly
in these cells. However, under conditions identical to robust
activation of the ERK1 and ERK2 in JC-R3 cells, FSH stimulation of this
parameter was very low or marginal in JC-R1 cells (compare Figs.
6 and 5B). Likewise, forskolin
that enhanced cAMP in JC-R3 cells had no influence on ERK1 and ERK2
activation (Fig. 6, bottom panel). These data clearly suggest that in the granulosa cell system as studied here,
intracellular cAMP is unable to induce the activation of ERK1/2.

View larger version (38K):
[in this window]
[in a new window]
|
Fig. 6.
Influence of cAMP activating mechanisms on
ERK1/ERK2 phosphorylation in JC-R1 and JC-R3 cells. A,
serum-starved JC-R1 cells were stimulated with 100 ng/ml rFSH for
different time intervals and probed as indicated in previous figures.
The intensity of the band in each lane represents the degree of
ERK1/ERK2 phosphorylation. Cells treated with 10% serum for 10 min
served as a positive control. Equal loading is shown by ERK1/2
intensity in each lane. B, serum-starved JC-R3 cells were
stimulated with different concentrations of forskolin
(µM) for 10 min as shown. The intensity of the band in
each lane represents the degree of ERK1/ERK2 phosphorylation. There is
no activation by forskolin at any concentration. 10% serum-stimulated
cells for 10 min served as a positive control. Relative ERK1/2
activation status in both panels was calculated as in Fig.
5A and is shown on the right.
|
|
Role of Calcium--
Downward changes in cellular Ca2+
are detrimental in the regulation of Ras/MAP kinase pathway through
mechanisms that are not completely understood. Pretreating the JC-R3
cells with either intracellular calcium chelator BAPTA/AM
(10 2 M) or exposing the cells to an
extracellular calcium chelator like EGTA (10 3
M), completely blocked MAP kinase activation (Fig.
7). This suggests that calcium influx
plays a major role in the FSH controlled events that may induce cell
proliferation. We also tested whether activation of PKC will have any
effect on MAP kinases in these cells and as seen in Fig. 7, phorbol
12-myristate 13-acetate at a concentration of 200 nM,
induced a transient increase in ERK1/2 phosphorylation suggesting
positive regulation of PKC in MAP kinase activation. Pretreating JC-R3
cells with Ag 18 (10 5 M), a tyrosine kinase
inhibitor also reduced the FSH-induced ERK1 and ERK2 activation. The
lower panel shows the expression of MAP kinase verified as
internal control.

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 7.
Effect of intra- or extracellular calcium
chelator on FSH-induced ERK1/ERK2 activation in JC-R3 cells.
Serum-starved JC-R3 granulosa cells were stimulated with either rhFSH
(100 ng/ml) or phorbol 12-myristate 13-acetate (PMA) (200 nM) for 10 min. In some experiments, cells were pretreated
for 30 min with intra- or extracellular Ca2+ chelator
BAPTA/AM (10 2 mol/liter) or EGTA (10 3
mol/liter). The cells were lysed in lysis buffer as described under
"Materials and Methods," 5 µg of soluble cell protein was
separated on 10% SDS-PAGE and transferred to polyvinylidene difluoride
membrane. The blot was probed with phospho-specific ERK1/2 antibody
(1:1000) and same blot was stripped and reprobed with ERK1/2 antibody
to evaluate equal loading of protein (see bottom).
|
|
Role of PI 3-Kinase Pathway in ERK1/ERK2 Activation in JC-R3
Cells--
Since the role of PI-3 pathway as an upstream regulator of
MAP kinase activation was reported in some cell lines (34, 35), we
examined the activation of Akt (protein kinase), a downstream regulatory molecule in PI-3 pathway in JC-R3 cells. FSH did not activate Akt phosphorylation (Fig.
8A). However, in cells treated with serum Akt phosphorylation was clearly evident. When we pretreated JC-R3 cells with the specific PI 3-kinase inhibitor LY294002 there was
no effect on ERK1/2 activation (Fig. 8B). Together these
data suggest that FSH has no influence on PI-3 activation and this pathway is not involved in the activation of ERK1/2 in JC-R3 cells.

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 8.
The effect of FSH on the PI 3-kinase pathway
in JC-R3 granulosa cells. A, granulosa cells expressing R3
were stimulated with rhFSH (100 ng/ml) for different time periods or
with 10% serum for 30 min. Cell protein extract was prepared as
described under "Materials and Methods." An equal amount (100 µg)
of protein was separated on 10% SDS-PAGE and immunoblotted with
phospho-Akt (1:1000) and Akt (1:1000) antibodies as shown.
B, JC-R3 cells stably expressing R3 receptor were pretreated
for 30 min with different concentrations of PI 3-kinase inhibitor
LY294002 as shown. Subsequently the cells were stimulated with FSH 100 ng/ml for 10 min as described under "Materials and Methods." The
upper panel represents the phospho-specific ERK1/ERK2
activation and lower panel represents ERK1/ERK2
expression.
|
|
Role of MAP Kinases in the Growth Promoting Effects of FSH in JC-R3
Cells--
To examine the contribution of MAP kinase signaling to the
stimulatory effect of FSH on cell cycle progression, the cells were
treated with hormone and BrdUrd incorporation in S-phase cells was
quantitated by flow cytometry. Fig.
9A compares the response of
FSH in JC-R3 or JC-R1 and JC-vector cells. Biphasic effects were
evident in both JC-R3 and JC-R1 cells. In JC-R3 cells maximal
stimulation was seen with 1 ng/ml FSH. There was a 2.5-fold increase in
the BrdUrd-positive cells that gradually decreased with increasing FSH
concentration. At high hormone concentration there was no effect (Fig.
9A). Under identical conditions, JC-R1 cells also showed a
moderate increase in BrdUrd-positive S-phase cells. Fig. 9B
shows the time course of BrdUrd incorporation in JC-R3 cells with
increases seen up to 3 h. Long periods of growth promoting action
of FSH was measured using [3H]thymidine incorporation in
both JC-R3 and JC-R1 cells at two hormone concentrations that was
stimulatory in the above study (Fig. 9A). At 24 h DNA
synthesis (Fig. 9C) is significantly higher in JC-R3 than in
JC-R1 under identical conditions. Fig.
10A shows that inhibition of
MAP kinase activation with MEK inhibitor PD 98059 prior to BrdUrd
treatment effectively blocked the BrdUrd incorporation in JC-R3 cells
indicating the potential role of MAP kinases in granulosa cell
proliferation. However, pretreating cells either with KT 5720 or H89
(10 5 M) caused no change in BrdUrd
incorporation confirming that MAP kinase activation in these cells is
mediated by cAMP independent pathways. Parallel experiments with JC-R1
cells (Fig. 10B) show that blocking MEK activity by PD98509
or inhibiting intracellular calcium has no effect on BrdUrd labeling
but a partial reduction is seen with PKA inhibitor H89. In summary
these data suggest the presence of potential alternative pathways in
granulosa cell proliferation.

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 9.
Mitogenic actions of FSH on transfected
granulosa cells. The top section (A) shows
responses of granulosa cell proliferation induced by increasing
concentration of FSH. Granulosa cells transfected with either oFSH-R1
or oFSH-R3 and vector control were growth arrested in serum-free medium
and treated with varying concentrations of rhFSH and BrdUrd for 1 h. BrdUrd labeling indices of S-phase cells are represented in the
figure as % of BrdUrd-positive cells. Data are the mean ± S.E.
of triplicate determinations. In the middle section
(B) are shown the time course of mitogenic action of rhFSH
on JC-R3 cells. Both JC-vector and JC-R3 granulosa cells in serum-free
medium were treated with rFSH and BrdUrd as indicated. Cells were
harvested at different times after FSH treatment for analysis. The
bottom section (C) shows DNA synthesis as
measured by thymidine incorporation in cultured granulosa cells
expressing either FSH-R3 or FSH-R1 and without receptor (JC-vector).
Cells were incubated with or without FSH (1 and 10 ng/ml) for 24 h
in the presence of 1 µCi of [3H]thymidine. The data are
mean ± S.E. (n = three per experiment) with *
indicating statistically significant differences from control.
|
|

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 10.
Effect of specific signaling pathway
inhibitors on proliferation in JC-R3 and JC-R1 cells. A
shows the inhibition of FSH-induced proliferation in JC-R3 cells by MEK
inhibitor PD98059 and intracellular calcium inhibitor BAPTA/AM. JC-R3
cells were treated with PD98059 (10 5 M),
BAPTA/AM (10 2 M), KT5720 (10 5
M), H89 (10 5 M), or LY294002
(10 6 M) for 30 min prior to agonist
stimulation (1 ng/ml for 1 h) and BrdUrd labeling. BrdUrd-labeled
S-phase cells are expressed as relative % of BrdUrd-positive cells.
Significant differences are represented by the asterisk. B
represents the effect of different inhibitors on FSH-induced
proliferation in JC-R1 cells. JC-R1 cells were treated with PD98059
(10 5 M), BAPTA/AM (10 2
M), H89 (10 5 M), and LY294002
(10 6 M) for 30 min prior to FSH (1 ng/ml,
1 h) stimulation and BrdUrd labeling. BrdUrd-labeled S-phase cells
are expressed relative % of BrdUrd-positive cells. Significant
differences are represented by the asterisk.
|
|
Steroidogenic Response in Granulosa Cells--
JC-R3 cells were
stimulated in minimal medium with rhFSH in the presence or absence of
0.1 µM androstenedione, which serves as the substrate for
the enzyme aromatase. This enzyme converts the androgen to the phenolic
steroid estradiol-17 . Fig. 11
(top panel) reveals a concentration dependent increase in
estradiol-17 production. Significant stimulation evident at 10 ng/ml
FSH increased in a linear manner up to 200 ng/ml, the highest
concentration that was tested in our study. However, it should be noted
that these effects, which normally become apparent only after prolonged (24-48 h) incubation of granulosa cells, are weak when compared with
the rapid and robust stimulation of other parameters shown in previous
figures (Figs. 5 and 8-10) for JC-R3 cells. Since the steroidogenic
action of FSH mediated by the Gs-coupled human FSH-R1 is
well established for progesterone production in transfected mouse
adrenal Y1 cells (36), we compared the actions of the hormone in
granulosa cells transfected individually with the two receptors. Fig.
11 (bottom) depicts the estradiol production in transfected
cells lines expressing either R1 or R3 receptors. Cells with R3
produced a 3-fold increase in estradiol production compared with
untransfected cells in presence of 0.1 µM
androstenedione. Cells expressing R1 caused a 7-fold increase in
estradiol. As the cells bearing and equivalent number of receptors were
treated under identical conditions and the effect was reproducible, the differences in the estradiol production induced by these two receptors may be attributable to differences in their mode of action during steroidogenesis. Irrespective of the type of FSH-R present in the
transfected granulosa cell, addition of the non-hormonal agent forskolin resulted in the same level of activation of steroidogenesis (Fig. 11B).

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 11.
Activation of steroidogenesis in granulosa
cells transfected with FSH-R3. Top, granulosa cells were
cultured in DMEM containing 5% fetal bovine serum for 24 h,
washed with PBS, and incubated for an additional 12 h in
serum-free medium. Cells were then stimulated with rhFSH in the
presence or absence of 0.1 µM androstenedione as
substrate for the enzyme aromatase for 48 h. Bottom,
for the experiment with JC-R3 and JC-R1 cells the respective cDNAs
are transfected and cultured for 12 h in DMEM with 5% fetal
bovine serum. Subsequently, cells in serum-free medium were stimulated
with rFSH (100 ng/ml) in the presence of 0.1 µM
androstenedione for an additional 48 h. In both sets of
experiments the culture media were then collected and analyzed for
estradiol production by radioimmunoassay. Each point represents the
mean ± S.E. of three experiments, repeated twice. Significant
differences are represented by the asterisk. Note that both
JC-R3 and JC-R1 cells treated with forskolin produce the same amount of
estrogen.
|
|
 |
DISCUSSION |
During the growth and maturation of ovarian follicles, the
granulosa cells, which are the major cell type in this structure that
also contains the developing ovum, proliferate rapidly and undergo
differentiation in a precisely ordered sequence. This process includes
the acquisition of receptors for the glycoprotein hormone FSH in the
early stages of growth. It is known that FSH, a major regulator of
receptor(s) induction, increases FSH receptor mRNA and protein
levels both in vivo and in vitro (37, 38). The
rapid increase in FSH-induced DNA synthesis in the immature ovary well
before cAMP production (39), increased uptake of [3H]thymidine in preantral follicles (40), imply that
growth has been initiated by allowing the cells to enter the cell
cycle. Subsequently, checkpoints of the cell cycle-like cyclin D2 (41) and other control mechanisms determine the path of the granulosa cells
toward further development and differentiation (42). However, the
precise molecular nature of FSH receptors or the signaling mechanisms
that mediate hormonal induction of such mitotic activities during the
early stages of follicular growth have remained a mystery. According to
the present dogma in the glycoprotein hormone receptor field, the
diverse action(s) of the glycoprotein hormones is assumed to be
mediated solely by the G-protein-coupled heptahelical transmembrane receptor entity (43). Having cloned novel structural motifs of the
functional FSH receptor that differ from this topography and documented
expression of the corresponding protein in the ovary (12), we launched
a systematic attempt to define the role of the growth factor type I
receptor in ovarian cells to identify its signaling pathways. While
this report focuses on revealing the properties of the novel receptor
FSH-R3, we have included some studies comparing the
Gs-coupled receptor providing data on relative
differences in signaling.
Although variants of G-protein-coupled receptors suggestive of
differential coupling to diverse signaling pathways are documented (44), there had been no report of the creation of a new receptor motif
by alternative splicing mechanisms (10, 12). The functional data
presented here introduce a new paradigm in the study of cell regulation
by complex hormones and reveal that novel receptor motifs created by
splicing and expressed in the gonads are linked to discrete signaling
pathways. The recent availability of ovarian granulosa cells that can
be maintained in culture without differentiation and functional
endogenous FSH receptors (22, 23) (Fig. 1 this study) has afforded us
the opportunity to recreate target cells with unique receptor forms. In
this manner, signal transduction including steroidogenesis by
individual receptor motifs can be investigated without interference of
cross-talk that complicate analysis in cells derived from primary
cultures of animal tissues that may express more than one type of receptor.
Most previous studies have been conducted in non-target cells (4, 10,
21, 25, 36, 45, 46) that are incapable (except the Y1 cells used by
Kelton et al. (36)) of performing a steroidogenic function.
The demonstration of the R3 receptor on the surface of granulosa cells
extends previous findings of the expression of the novel receptor that
had been initially observed in HEK 293 cells (10, 12). The immunoblot
data (Fig. 2) using two different antibodies further suggests that this
receptor was expressed as a glycoprotein of 39 kDa. Evidence derived
from enzymatic deglycosylation of R3-transfected cells and the apparent
higher Mr in SDS-PAGE suggest that both the
consensus sites at Asn-174 and Asn-182 of the mature R3 receptor
protein are glycosylated.
The growth factor receptor type I motif for FSH was initially cloned
from the sheep testis (14) and ovary (12). Expression of the
corresponding protein has also been verified (12). The universal
participation of such alternatively spliced receptors in signaling
processes requires confirmation in other species. Thus, our first
demonstration that the R3 receptor also exists in the mouse ovary (Fig.
2) is significant. The specificity of our detection system for R3
protein was evident in the Western blots because only the wild type +/+
mouse ovary extracts showed the expression of this receptor protein
with a migration very similar to that of the receptor in
JC-R3-transfected cells. The complete absence of a protein band
corresponding to this as well as R1 in the ovaries of FSH receptor
knockout ( / ) mouse also proves that the entire repertoire of FSH
receptor motifs were eliminated in our knockout strategy causing
sterility in females (16).
Based on recent x-ray crystallographic evidence, the glycoprotein
hormone FSH and other members of this family have been modeled (47) as
having structural features that include the cystine knot motif that are
also present in many ligands that act as growth factors. The receptors
for these ligands and their signaling properties are different from the
G-protein-coupled receptors. The discovery of a growth factor type
receptor R3 for FSH is consistent with the structural predictions for
the hormone and is strongly supported by the data described in this
study which show that signaling mechanisms other than the G-proteins
are also utilized by the hormone. Thus, its linkage to the activation
of MAP kinase pathways as demonstrated here now provides a new
perspective in understanding glycoprotein hormone action. The MAP
kinase signaling cascade, an important regulator of cell cycle
progression, has been used as a biochemical marker to evaluate the
status of hormones and growth factors as mitogens (48).
The FSH-R3 receptor itself consists near its carboxyl terminus the
sequence PVILSP (10, 12, 14), which represents a potential consensus
motif (PXnS/TP, where X is basic or neutral residue) for phosphorylation by MAP kinases (49). Because this motif
appears only after alternative splicing at the 8th exon of the FSH
receptor gene (10, 14) we can argue that the change must have
structural and functional significance. Structurally, the change led to
the appearance of a single transmembrane domain for FSH-R3 as well as
the other accompanying motifs that couple to alternative signaling
pathways. This consensus site is present in the analogous hTSH receptor
variant in the thyroid where this transcript is also generated by
alternative splicing at exon 8 (50). As both FSH and TSH are mitogenic
hormones and stimulate cell proliferation in their respective target
tissues, presence of the R3 type of motif may have great significance
in receptor function and dynamics. FSH-induced receptor phosphorylation
(Fig. 4) in JC-R3 cells suggest that some of the serine residues in COOH-terminal end may be involved in the modification. However, the
mechanisms by which the receptor is phosphorylated remain to be
clarified. Receptor autophosphorylation is unlikely because the COOH
terminus lacks intrinsic kinase domains. The effects of gonadotropin
receptor phosphorylation in general have recently been reviewed (51)
and other investigators studying the R1-type FSH receptor in
transfected HEK 293 cells (52) have shown that phosphorylation
modulates receptor uncoupling and internalization.
Gonadotropins are known to increase the MAP kinases in ovarian
granulosa cells collected from intact animals (18, 19). The differences
in the activation of ERK1/ERK2 by cAMP and gonadotropins (LH and FSH)
may suggest that gonadotropins activate these enzymes via pathways that
operate, at least in part, independent of cAMP (19). However, the
precise receptor mechanisms identifying how FSH may regulate MAP kinase
activation and its subsequent role in granulosa cell proliferation was
unknown. It has long been appreciated that a significant elevation of
intracellular cAMP levels may potently inhibit cell proliferation and
division (53) but at lower concentration may have opposite effect (54).
However, FSH-induced cell proliferation in ovarian follicles is a major effect of the hormone, that may be incompatible with elevation of cAMP,
a second messenger that is clearly elevated by the R1 receptor (3, 36,
45, 46). Based on the data presented in Figs. 3, 5, 6, 8, and 9, we may
conclude that FSH signaling through the R3 receptor is a major
mechanism of MAP kinase activation and cell proliferation independent
of the cAMP pathway. The absence of ERK1/2 activation by forskolin
(Fig. 6B) an agent that promptly elevated cAMP in JC-R3
cells, and the complete abrogation of hormone-induced cell
proliferation by PD98059, a specific inhibitor of MAP kinase activity,
clearly justifies such a conclusion. Thus, our data provides a
mechanistic explanation for inferences drawn from studies on FSH action
in primary cultures (19). FSH action in JC-R3 cells increased BrdUrd
labeling of granulosa cell nuclei, in a hormone-specific manner. The
biphasic nature of this response and maximal stimulation obtained at
low concentration (Fig. 9) although intriguing, is typical of the
behavior exhibited by growth promoting hormones. This is further
confirmed by long term growth promoting effects of FSH both in R3 and
R1 cells by [3H]thymidine incorporation. Our data with
JC-R3 cells bearing a cloned FSH-R are consistent with the earlier
observation of Bley et al. (55), who also found that FSH had
a biphasic response on ovarian cellular growth in primary cultures.
Inhibition of phosphorylation of MEK1 by the specific MEK kinase
inhibitor PD 98059 or chelating intracellular calcium by BAPTA/AM
completely blocks the proliferative effects of FSH. These results
signify that activation of MEK1 is important for proliferative actions of FSH in granulosa cells that express the R3 receptor. Under identical
conditions blocking MEK1 activity or chelating intracellular calcium
had no effect on proliferation in JC-R1 cells (Fig. 10).
It has been well established that growth factors activate MAP kinases
in a variety of cell types (48) and that inhibitors of the activation
of the MAPK cascade block the mitogenic action of the growth factors
(56). These observations have been confirmed and extended in the
present study with the novel glycoprotein hormone receptor motif
FSH-R3. As both H89 and K57032, that are PKA inhibitors did not
significantly influence the FSH-induced proliferation and activation of
MAP kinase in FSH-R3-transfected cells, our conclusion that the FSH-R3
receptor utilizes other pathways to activate MAP kinase instead of
cAMP/PKA appears justified. This is further supported by the absence of
cAMP production by FSH in FSH-R3-transfected cells (Fig. 3). Our
investigations, designed solely to understand the signaling properties
of the novel FSH-R3 in an individual setting in cells that express only one type of receptor does not preclude a role for the
Gs-coupled FSH-R1 and the PKA pathway in cell
proliferation. Our results indeed support that FSH-R1 may also be
coupled to cell proliferation through other mechanisms which need to be
clarified in more detail. In addition to the differences noted above,
the phenotypic characteristics of granulosa cells bearing one or the
other FSH receptor appears to be different. While JC-R1 cells that
produce cAMP in response to FSH promptly show the cell rounding
phenomenon as reported in other studies (36), the JC-R3 cells that
activate ERK1/2 do not display this behavior (data not shown).
Therefore, it is possible that the preponderance of one or the other
form of FSH receptors varying as the ovarian granulosa cells mature
might dictate the selection of different signaling pathways and
cross-talk that is likely to occur during rapid developmental changes.
The relation between hormone action, Ca2+ influx, MAP
kinase activation, and cell proliferation and steroidogenesis in JC-R3 cells can be integrated by our investigations. In a previous study, we
reported that, FSH induces Ca2+ influx in FSH-R3
transfected HEK 293 cells through L-voltage dependent pathways (21). As
the hormone induces Ca2+ in primary granulosa or Sertoli
cells but not in R1-transfected cells (see Refs. 21 and 57),
participation of a different receptor motif is likely. Taken together
with the results of the present study, the implication is clear that
FSH induces calcium influx in target granulosa cells via the FSH-R3 and
the increased Ca2+ in the cytosol in turn leads to MAP
kinase activation.
Ca2+ influx is well known to activate MAP kinase in
cultured cells by several mechanisms (58, 59) including PKC activation of Ras (60). Since FSH-induced ERK activation in JC-R3 cells is
inhibited by a PKC inhibitor, the involvement of PKC pathways upstream
of ERK signaling is most likely. This conclusion is further supported
by data showing inhibition of ERK activation by intracellular or
extracellular Ca2+ chelators. Recent reports that PI
3-kinase can be involved in the regulation of ERK kinase pathway and PI
3-kinase can also be activated by Ca2+ influx (59) have led
to the implication of PI 3-kinase in downstream control of Ras in some
cellular systems (34, 35, 61-64). More importantly the PI 3-kinase
activity is also able to modulate the ERK/MAP kinase pathway (34, 35).
Since we did not observe any effect of the hormone on phosphorylation
of Akt and furthermore, a PI 3-kinase inhibitor did not influence the
MAP kinase activation, we suggest that mediation of FSH effects by PI
3-kinase is unlikely in the JC-R3 cells.
Another important new observation emerging from the current study is
that the growth factor type I receptor of FSH is also coupled to
steroidogenic machinery albeit weakly. Therefore, a second pathway in
addition to the classical Gs-coupled signaling mechanism
may also be operative in granulosa cells. A hallmark of FSH action in
the ovarian granulosa cell is the synthesis of estrogen, which
subsequently activates transcription of numerous genes via its nuclear
receptors. Based on the data shown in Fig. 11, the conclusion is
inescapable that cells expressing FSH-R3 indeed secreted
estradiol-17 into the medium in response to the hormone. However,
under identical conditions the full-length FSH-R1, which activates the
Gs-signaling systems is more efficient in inducing
steroidogenesis. The identification of two different pathways for
hormone signaling including steroidogenesis may represent a back up
mechanism utilized by a dynamic system such as the granulosa cell that
has to perform diverse functions.
In conclusion, these results for the first time demonstrate that a
novel type of FSH receptor (R3) exhibiting features of a growth factor
type I receptor is primarily responsible activation of the ERK pathway
in ovarian granulosa cells. This was essentially independent of
cAMP/PKA-mediated events but dependent upon Ca2+ influx and
PKC pathway. The identification of putative transducers that directly
induces Ca2+ influx and activation of MAP kinases remain to
be determined. Future challenges include the recognition and eventual
identification of interacting protein(s) partners for each specific FSH
receptor type within the target cell. Differences in modulation of
these events may dictate the final commitment of the cell to undergo proliferation and/or produce steroids.
 |
ACKNOWLEDGEMENTS |
We are grateful to the NIDDKs National
Hormone and Pituitary Program and Dr. A. F. Parlow, UCLA, for the
supply of recombinant hormones used in the study, Dr. A. Levitzki (Hebrew University, Jerusalem, Israel) for supplying
the Ag18, and Dr. G. Thibault of our institute for providing reagents
for cAMP assay. The technical help of Maria Gerdes and secretarial
assistance of Odile Royer in preparation of this manuscript is greatly appreciated.
 |
FOOTNOTES |
*
This work was supported by a grant from the Medical Research
Council of Canada.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed: Molecular
Reproduction Research Laboratory, Clinical Research Institute of
Montreal, 110 Pine Avenue West, Montreal, Quebec, Canada H2W 1R7. Tel.: 514-987-5582; Fax: 514-987-5585; E-mail: sairamm@ircm.qc.ca.
Published, JBC Papers in Press, June 26, 2000, DOI 10.1074/jbc.M003206200
 |
ABBREVIATIONS |
The abbreviations used are:
FSH, follicle-stimulating hormone;
rhFSH, recombinant human
follicle-stimulating hormone (follitropin);
rhCG, recombinant-human
chorionic gonadotropin;
LH, luteinizing hormone (lutropin);
ERK, extracellular-regulated kinase;
ERK1/2-P, activated ERK;
MAPK, mitogen-activated protein kinase;
DMEM, Dulbecco's modified Eagle's
medium;
MEK, mitogen-activated protein kinase/extracellular-regulated
kinase;
PBS, phosphate-buffered saline;
RT-PCR, reverse
transcriptase-polymerase chain reaction;
bp, base pair(s);
BrdUrd, 5-bromodeoxyuridine;
PKC, protein kinase C;
BAPTA, 1,2-bis(O-aminophenoxy)ethane-N,N,N',N'-tetraacetic
acid;
PI 3-kinase, phosphoinositol 3-kinase.
 |
REFERENCES |
| 1.
|
Loganzo, F., Jr.,
and Fletcher, P. W.
(1992)
Mol. Endocrinol.
6,
1259-1267
|
| 2.
|
Griswold, M. D.
(1993)
in
The Sertoli Cell
(Russell, L. D.
, and Griswold, M. D., eds)
, pp. 493-508, Cache River Press, Clearwater, FL
|
| 3.
|
Simoni, M.,
Gromoll, J.,
and Nieschlag, E.
(1997)
Endocr. Rev.
18,
739-773
|
| 4.
|
Braun, T.,
Schofield, P. R.,
and Sprengel, R.
(1991)
EMBO J.
10,
1885-1890
|
| 5.
|
Sairam, M. R.,
Jiang, L. G.,
Khan, H.,
and Yarney, T. A.
(1996)
Biochem. Biophys. Res. Commun.
226,
717-722
|
| 6.
|
Sairam, M. R.,
and Subbarayan, V. S. R.
(1997)
Mol. Reprod. Dev.
48,
480-487
|
| 7.
|
Sharp, P. A.
(1994)
Cell
77,
805-815
|
| 8.
|
Loosfelt, H.,
Misrahi, M.,
Atger, M.,
Salesse, R.,
Vu Hai-Luu Thi, M. T.,
Jolivet, A.,
Guiochon-Mantel, A.,
Sar, S.,
Jallal, B.,
Garnier, J.,
and Milgrom, E.
(1989)
Science
245,
525-528
|
| 9.
|
Themmen, A. P. N.,
Kraaij, R.,
and Grootegoed, J. A.
(1994)
Mol. Cell. Endocrinol.
100,
15-19
|
| 10.
|
Sairam, M. R.,
Jiang, L. G.,
Yarney, T. A.,
and Khan, H.
(1997)
Mol. Reprod. Dev.
48,
471-479
|
| 11.
|
Yarney, T. A.,
Jiang, L. G.,
Khan, H.,
MacDonald, E. A.,
Laird, D. W.,
and Sairam, M. R.
(1997)
Mol. Reprod. Dev.
48,
458-470
|
| 12.
|
Babu, P. S.,
Jiang, J.,
Sairam, A. M.,
Touyz, R. M.,
and Sairam, M. R.
(1999)
Mol. Cell. Biol. Res. Commun.
2,
21-27
|
| 13.
|
Yarney, T. A.,
Fahmy, M. A.,
Sairam, M. R.,
Khan, H.,
and MacDonald, E. A.
(1997)
J. Mol. Endocrinol.
18,
113-125
|
| 14.
|
Khan, H.,
Yarney, T. A.,
and Sairam, M. R.
(1993)
Biochem. Biophys. Res. Commun.
190,
888-894
|
| 15.
|
Kumar, T. R.,
Wang, Y.,
Lu, N.,
and Matzuk, M. M.
(1997)
Nat. Genet.
15,
201-204
|
| 16.
|
Dierich, A.,
Sairam, M. R.,
Monaco, L.,
Fimia, G. M.,
Gansmuller, A.,
LeMeur, M.,
and Sassone-Corsi, P.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
13612-13617
|
| 17.
|
Elion, E. A.
(1998)
Science
281,
1625-1626
|
| 18.
|
Das, S.,
Maizels, E. T.,
DeManno, D.,
St. Clair, E.,
Adam, S. A.,
and Hunzicker-Dunn, M.
(1996)
Endocrinology
137,
967-974
|
| 19.
|
Cameron, M. R.,
Foster, J. S.,
Bukovsky, A.,
and Wimalasena, J.
(1996)
Biol. Reprod.
55,
111-119
|
| 20.
|
Pennybacker, M.,
and Herman, B.
(1991)
Mol. Cell. Endocrinol.
80,
11-20
|
| 21.
|
Touyz, R. M.,
Jiang, L.,
and Sairam, M. R.
(2000)
Biol. Reprod.
62,
1067-1074
|
| 22.
|
Chedrese, P. J.,
Rodway, M. R.,
Swan, C. L.,
and Gillio-Meina, C.
(1998)
J. Mol. Endocrinol.
20,
287-292
|
| 23.
|
Rodway, M. R.,
Swan, C. L.,
Gillio-Meina, C.,
Crellin, N. K.,
Flood, P. F.,
and Chedrese, P. J.
(1999)
Mol. Cell. Encocrinol.
148,
87-94
|
| 24.
|
Khan, H.,
Jiang, L. G.,
Jayashree, G. N.,
Yarney, T. A.,
and Sairam, M. R.
(1997)
J. Mol. Endocrinol.
19,
183-190
|
| 25.
|
Liu, X.,
DePasquale, J.,
Griswold, M. D.,
and Dias, J. A.
(1994)
Endocrinology
135,
682-691
|
| 26.
|
Davis, D.,
Liu, X.,
and Segaloff, D. L.
(1995)
Mol. Endocrinol.
9,
159-170
|
| 27.
|
Gasinska, A.,
and Wilson, G. D.
(1988)
Br. J. Radiol.
61,
133-139
|
| 28.
|
Terry, N. H.,
White, R. A.,
Meistrich, M. L.,
and Calkins, D. P.
(1991)
Cytometry
12,
234-241
|
| 29.
|
Nakamura, K.,
Krupnick, J. G.,
Benovic, J. L.,
and Ascoli, M.
(1998)
J. Biol. Chem.
273,
24346-24354
|
| 30.
|
Moudgal, N. R.,
Sairam, M. R.,
Krishnamurthy, H. N.,
Sridhar, S.,
Krishnamurthy, H.,
and Khan, H.
(1997)
Endocrinology
138,
3065-3068
|
| 31.
|
Dattatreyamurty, B.,
and Reichert, L. E., Jr.
(1992)
Endocrinology
131,
2437-2445
|
| 32.
|
Minegishi, T.,
Delgado, C.,
and Dufau, M. L.
(1989)
Proc. Natl. Acad. Sci. U. S. A.
86,
1470-1474
|
| 33.
|
Touraine, P.,
Beau, I.,
Gougeon, A.,
Medwi, G.,
Desroches, A.,
Richard, C.,
Detoeuf, M.,
Daniel, B.,
Pieur, M.,
Zorn, J. R.,
Milgrom, E.,
Kuttenn, F.,
and Misrahi, M.
(1999)
Mol. Endocrinol.
23,
1844-1854
|
| 34.
|
Grammer, T. C.,
and Blenis, J.
(1997)
Oncogene
14,
1635-1642
|
| 35.
|
King, W. G.,
Mattaliano, M. D.,
Chan, T. O.,
Tsichlis, P. N.,
and Brugge, J. S.
(1997)
Mol. Cell. Biol.
17,
4406-4418
|
| 36.
|
Kelton, C. A.,
Cheng, S. V. Y.,
Nugent, N. P.,
Schweickhardt, R. L.,
Rosenthal, J. L.,
Overton, S. A.,
Wands, G. D.,
Kuzeja, J. B.,
Luchette, C. A.,
and Chappel, S. C.
(1992)
Mol. Cell. Endocrinol.
89,
141-151
|
| 37.
|
Camp, T. A.,
Rahal, J. O.,
and Mayo, K. E.
(1991)
Mol. Endocrinol.
5,
1405-1417
|
| 38.
|
LaPolt, P. S.,
Tilly, J. L.,
Aihara, T.,
Nishimori, K.,
and Hsueh, A. J. W.
(1992)
Endocrinology
130,
1289-1295
|
| 39.
|
Delidow, B. C.,
White, B. A.,
and Peluso, J. J.
(1990)
Endocrinology
126,
2302-2306
|
| 40.
|
Roy, S. K.,
and Treacy, B. J.
(1993)
Fertil. Steril.
59,
783-790
|
| 41.
|
Sicinski, P.,
Donaher, J. L.,
Geng, Y.,
Parker, S. B.,
Gardner, H.,
Park, M. Y.,
Robker, R. L.,
Richards, J. S.,
McGinnis, L. K.,
Biggers, J. D.,
Eppig, J. J.,
Bronson, R. T.,
Elledge, S. J.,
and Weinberg, R. A.
(1996)
Nature
384,
470-474
|
| 42.
|
Robker, R. L.,
and Richards, J. S.
(1998)
Biol. Reprod.
59,
476-482
|
| 43.
|
Ji, T. H.,
Grossman, M.,
and Ji, I.
(1998)
J. Biol. Chem.
273,
17299-17302
|
| 44.
|
Chew, S. L.
(1997)
Trends Endocrinol. Metab.
8,
405-413
|
| 45.
|
Sprengel, R.,
Braun, T.,
Nikolics, K.,
Segaloff, D. L.,
and Seeburg, P. H.
(1990)
Mol. Endocrinol.
4,
525-530
|
| 46.
|
Yarney, T. A.,
Sairam, M. R.,
Khan, H.,
Ravindranath, N.,
Payne, S.,
and Seidah, N. G.
(1993)
Mol. Cell. Endocrinol.
93,
219-226
|
| 47.
|
Lapthorn, A. J.,
Harris, D. C.,
Littlejohn, A.,
Lustbader, J. W.,
Canfield, R. E.,
Machin, K. J.,
Morgan, F. J.,
and Isaacs, N. W.
(1994)
Nature
369,
455-461
|
| 48.
|
Campbell, J. S.,
Seger, R.,
Graves, J. D.,
Graves, L. M.,
Jensen, A. M.,
and Krebs, E. G.
(1995)
Recent Prog. Horm. Res.
50,
131-159
|
| 49.
|
Gonzalez, F. A.,
Raden, D. L.,
and Davis, R. J.
(1991)
J. Biol. Chem.
266,
22159-22163
|
| 50.
|
Graves, P. N.,
Tomer, Y.,
and Davies, T. F.
(1992)
Biochem. Biophys. Res. Commun.
187,
1135-1143
|
| 51.
|
Ascoli, M.
(1996)
Biochem. Pharmacol.
52,
1647-1655
|
| 52.
|
Quintana, J.,
Hipkin, R. W.,
Sanchez-Yague, J.,
and Ascoli, M.
(1994)
J. Biol. Chem.
269,
8772-8779
|
| 53.
|
Cook, S. J.,
and McCormick, F.
(1993)
Science
262,
1069-1072
|
| 54.
|
Frodin, M.,
Peraldi, P.,
and van Obberghen, E.
(1994)
J. Biol. Chem.
269,
6207-6214
|
| 55.
|
Bley, M. A.,
Saragueta, P. E.,
and Baranao, J. L.
(1997)
J. Steroid Biochem. Mol. Biol.
62,
11-19
|
| 56.
|
Alessi, D. R.,
Cuenda, A.,
Cohen, P.,
Dudley, D. T.,
and Saltiel, A. R.
(1995)
J. Biol. Chem.
270,
27489-27494
|
| 57.
|
Shibata, E. F.,
Matsuda, J. J.,
Volk, K. A.,
Collison, K. A.,
and Segaloff, D. L.
(1992)
Endocrinology
131,
979-981
|
| 58.
|
Thomas, S. M.,
DeMarco, M.,
D'Arcangelo, G.,
Halegoua, S.,
and Brugge, J. S.
(1992)
Cell
68,
1031-1040
|
| 59.
|
Miller, T. M.,
Tansey, M. G.,
Johnson, E. M., Jr.,
and Creedon, D. J.
(1997)
J. Biol. Chem.
272,
9847-9853
|
| 60.
|
Hallberg, B.,
Ashcroft, M.,
Loeb, D. M.,
Kaplan, D. R.,
and Downward, J.
(1998)
Oncogene
17,
691-697
|
| 61.
|
Rodriguez-Viciana, P.,
Warne, P. H.,
Dhand, R.,
Vanhaesebroeck, B.,
Gout, I.,
Fry, M. J.,
Waterfield, M. D.,
and Downward, J.
(1994)
Nature
370,
508-509
|
| 62.
|
Kodaki, T.,
Woscholski, R.,
Hallberg, B.,
Rodriguez-Viciana, P.,
Downward, J.,
and Parker, P. J.
(1994)
Current Biology
4,
798-806
|
| 63.
|
Rodriguez-Viciana, P.,
Warne, P. H.,
Vanhaesebroeck, B.,
Waterfield, M. D.,
and Downward, J.
(1996)
EMBO J.
15,
2442-2451
|
| 64.
|
Klinghoffer, R. A.,
Duckworth, B.,
Valius, M.,
Cantley, L.,
and Kazlauskas, A.
(1996)
Mol. Cell. Biol.
16,
5905-5914
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
J.-H. Choi, C.-L. Chen, S. L. Poon, H.-S. Wang, and P. C K Leung
Gonadotropin-stimulated epidermal growth factor receptor expression in human ovarian surface epithelial cells: involvement of cyclic AMP-dependent exchange protein activated by cAMP pathway
Endocr. Relat. Cancer,
March 1, 2009;
16(1):
179 - 188.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Sen, L. Lv, N. Bello, J. J. Ireland, and G. W. Smith
Cocaine- and Amphetamine-Regulated Transcript Accelerates Termination of Follicle-Stimulating Hormone-Induced Extracellularly Regulated Kinase 1/2 and Akt Activation by Regulating the Expression and Degradation of Specific Mitogen-Activated Protein Kinase Phosphatases in Bovine Granulosa Cells
Mol. Endocrinol.,
December 1, 2008;
22(12):
2655 - 2676.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-P. Lai, S. Lai, F. Tuluc, M. F. Tansky, L. E. Kilpatrick, S. E. Leeman, and S. D. Douglas
Differences in the length of the carboxyl terminus mediate functional properties of neurokinin-1 receptor
PNAS,
August 26, 2008;
105(34):
12605 - 12610.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. O. Belo, M. R. Sairam, and A. M. dos Reis
Impairment of the Natriuretic Peptide System in Follitropin Receptor Knockout Mice and Reversal by Estradiol: Implications for Obesity-Associated Hypertension in Menopause
Endocrinology,
March 1, 2008;
149(3):
1399 - 1406.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M Mihm, P J Baker, L M Fleming, A M Monteiro, and P J O'Shaughnessy
Differentiation of the bovine dominant follicle from the cohort upregulates mRNA expression for new tissue development genes
Reproduction,
February 1, 2008;
135(2):
253 - 265.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Sen, A. Bettegowda, F. Jimenez-Krassel, J. J. Ireland, and G. W. Smith
Cocaine- and Amphetamine-Regulated Transcript Regulation of Follicle-Stimulating Hormone Signal Transduction in Bovine Granulosa Cells
Endocrinology,
September 1, 2007;
148(9):
4400 - 4410.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Dos Santos, M.-N. Dieudonne, M.-C. Leneveu, R. Pecquery, V. Serazin, and Y. Giudicelli
In vitro effects of chorionic gonadotropin hormone on human adipose development
J. Endocrinol.,
August 1, 2007;
194(2):
313 - 325.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-H. Choi, A. S. T. Wong, H.-F. Huang, and P. C. K. Leung
Gonadotropins and Ovarian Cancer
Endocr. Rev.,
June 1, 2007;
28(4):
440 - 461.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. C.K. Leung and J.-H. Choi
Endocrine signaling in ovarian surface epithelium and cancer
Hum. Reprod. Update,
March 1, 2007;
13(2):
143 - 162.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Sahmi, E. S Nicola, and C. A Price
Hormonal regulation of cytochrome P450 aromatase mRNA stability in non-luteinizing bovine granulosa cells in vitro.
J. Endocrinol.,
July 1, 2006;
190(1):
107 - 115.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K.-Y. Kim, K.-C. Choi, S.-H. Park, N. Auersperg, and P. C. K. Leung
Extracellular Signal-Regulated Protein Kinase, But Not c-Jun N-Terminal Kinase, Is Activated by Type II Gonadotropin-Releasing Hormone Involved in the Inhibition of Ovarian Cancer Cell Proliferation
J. Clin. Endocrinol. Metab.,
March 1, 2005;
90(3):
1670 - 1677.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Steinmetz, H. A. Wagoner, P. Zeng, J. R. Hammond, T. S. Hannon, J. L. Meyers, and O. H. Pescovitz
Mechanisms Regulating the Constitutive Activation of the Extracellular Signal-Regulated Kinase (ERK) Signaling Pathway in Ovarian Cancer and the Effect of Ribonucleic Acid Interference for ERK1/2 on Cancer Cell Proliferation
Mol. Endocrinol.,
October 1, 2004;
18(10):
2570 - 2582.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Grover, M. R. Sairam, C. E. Smith, and L. Hermo
Structural and Functional Modifications of Sertoli Cells in the Testis of Adult Follicle-Stimulating Hormone Receptor Knockout Mice
Biol Reprod,
July 1, 2004;
71(1):
117 - 129.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. J. Urban, Y. H. Bodenburg, J. Jiang, L. Denner, and J. Chedrese
Protein kinase C{iota} enhances the transcriptional activity of the porcine P-450 side-chain cleavage insulin-like response element
Am J Physiol Endocrinol Metab,
June 1, 2004;
286(6):
E975 - E979.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Yang and S. K. Roy
Follicle Stimulating Hormone-Induced DNA Synthesis in the Granulosa Cells of Hamster Preantral Follicles Involves Activation of Cyclin-Dependent Kinase-4 Rather Than Cyclin D2 Synthesis
Biol Reprod,
February 1, 2004;
70(2):
509 - 517.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. S. Coffler, K. Patel, M. H. Dahan, R. Y. Yoo, P. J. Malcom, and R. J. Chang
Enhanced Granulosa Cell Responsiveness to Follicle-Stimulating Hormone during Insulin Infusion in Women with Polycystic Ovary Syndrome Treated with Pioglitazone
J. Clin. Endocrinol. Metab.,
December 1, 2003;
88(12):
5624 - 5631.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Uma, P. Muraly, S. Verma-Kumar, and R. Medhamurthy
Determination of Onset of Apoptosis in Granulosa Cells of the Preovulatory Follicles in the Bonnet Monkey (Macaca radiata): Correlation with Mitogen-Activated Protein Kinase Activities
Biol Reprod,
October 1, 2003;
69(4):
1379 - 1387.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Yang, A. Balla, N. Danilovich, and M. R. Sairam
Developmental and Molecular Aberrations Associated with Deterioration of Oogenesis During Complete or Partial Follicle-Stimulating Hormone Receptor Deficiency in Mice
Biol Reprod,
October 1, 2003;
69(4):
1294 - 1302.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Ulloa-Aguirre, C. Timossi, J. Barrios-de-Tomasi, A. Maldonado, and P. Nayudu
Impact of Carbohydrate Heterogeneity in Function of Follicle-Stimulating Hormone: Studies Derived from in Vitro and in Vivo Models
Biol Reprod,
August 1, 2003;
69(2):
379 - 389.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Schmierer, M. K. Schuster, A. Shkumatava, and K. Kuchler
Activin A Signaling Induces Smad2, but Not Smad3, Requiring Protein Kinase A Activity in Granulosa Cells from the Avian Ovary
J. Biol. Chem.,
May 30, 2003;
278(23):
21197 - 21203.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Srisuparp, Z. Strakova, A. Brudney, S. Mukherjee, S. Reierstad, M. Hunzicker-Dunn, and A. T. Fazleabas
Signal Transduction Pathways Activated by Chorionic Gonadotropin in the Primate Endometrial Epithelial Cells
Biol Reprod,
February 1, 2003;
68(2):
457 - 464.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K.-C. Choi, C.-J. Tai, C.-R. Tzeng, N. Auersperg, and P. C.K. Leung
Adenosine Triphosphate Activates Mitogen-Activated Protein Kinase in Pre-Neoplastic and Neoplastic Ovarian Surface Epithelial Cells
Biol Reprod,
January 1, 2003;
68(1):
309 - 315.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Manikkam, Y. Li, B. M. Mitchell, D. E. Mason, and L. C. Freeman
Potassium Channel Antagonists Influence Porcine Granulosa Cell Proliferation, Differentiation, and Apoptosis
Biol Reprod,
July 1, 2002;
67(1):
88 - 98.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K.-C. Choi, S. K. Kang, C.-J. Tai, N. Auersperg, and P. C. K. Leung
Follicle-Stimulating Hormone Activates Mitogen-Activated Protein Kinase in Preneoplastic and Neoplastic Ovarian Surface Epithelial Cells
J. Clin. Endocrinol. Metab.,
May 1, 2002;
87(5):
2245 - 2253.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. S. Babu, D. L. Bavers, F. Beuschlein, S. Shah, B. Jeffs, J. L. Jameson, and G. D. Hammer
Interaction Between Dax-1 and Steroidogenic Factor-1 in Vivo: Increased Adrenal Responsiveness to ACTH in the Absence of Dax-1
Endocrinology,
February 1, 2002;
143(2):
665 - 673.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. R. West, N. E. Carlson, J. S. Lee, A. S. McNeilly, T. P. Sharma, W. Ye, and V. Padmanabhan
Acidic Mix of FSH Isoforms Are Better Facilitators of Ovarian Follicular Maturation and E2 Production than the Less Acidic
Endocrinology,
January 1, 2002;
143(1):
107 - 116.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Krishnamurthy, R. Kats, N. Danilovich, D. Javeshghani, and M. Ram Sairam
Intercellular Communication Between Sertoli Cells and Leydig Cells in the Absence of Follicle-Stimulating Hormone-Receptor Signaling
Biol Reprod,
October 1, 2001;
65(4):
1201 - 1207.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Thiruppathi, S. Shatavi, J.A. Dias, E. Radwanska, and J.L. Luborsky
Gonadotrophin receptor expression on human granulosa cells of low and normal responders to FSH
Mol. Hum. Reprod.,
August 1, 2001;
7(8):
697 - 704.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Zarinan, A. Olivares, D. Soderlund, J.P. Mendez, and A. Ulloa-Aguirre
Changes in the biological:immunological ratio of basal and GnRH-releasable FSH during the follicular, pre-ovulatory and luteal phases of the human menstrual cycle
Hum. Reprod.,
August 1, 2001;
16(8):
1611 - 1618.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Krishnamurthy, P. Suresh Babu, C. R. Morales, and M. R. Sairam
Delay in Sexual Maturity of the Follicle-Stimulating Hormone Receptor Knockout Male Mouse
Biol Reprod,
August 1, 2001;
65(2):
522 - 531.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. S. Richards
Perspective: The Ovarian Follicle--A Perspective in 2001
Endocrinology,
June 1, 2001;
142(6):
2184 - 2193.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Bebia, J. P. Somers, G. Liu, L. Ihrig, A. Shenker, and A. J. Zeleznik
Adenovirus-Directed Expression of Functional Luteinizing Hormone (LH) Receptors in Undifferentiated Rat Granulosa Cells: Evidence for Differential Signaling through Follicle-Stimulating Hormone and LH Receptors
Endocrinology,
June 1, 2001;
142(6):
2252 - 2259.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. T. Maizels, A. Mukherjee, G. Sithanandam, C. A. Peters, J. Cottom, K. E. Mayo, and M. Hunzicker-Dunn
Developmental Regulation of Mitogen-Activated Protein Kinase-Activated Kinases-2 and -3 (MAPKAPK-2/-3) in Vivo during Corpus Luteum Formation in the Rat
Mol. Endocrinol.,
May 1, 2001;
15(5):
716 - 733.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
A. Ulloa-Aguirre, C. Timossi, and J.P. Mendez
Is there any physiological role for gonadotrophin oligosaccharide heterogeneity in humans?: I. Gondatrophins are synthesized and released in multiple molecular forms. A matter of fact
Hum. Reprod.,
April 1, 2001;
16(4):
599 - 604.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. S. Richards
New Signaling Pathways for Hormones and Cyclic Adenosine 3',5'-Monophosphate Action in Endocrine Cells
Mol. Endocrinol.,
February 1, 2001;
15(2):
209 - 218.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
P. S. Babu, N. Danilovich, and M. R. Sairam
Hormone-Induced Receptor Gene Splicing: Enhanced Expression of the Growth Factor Type I Follicle-Stimulating Hormone Receptor Motif in the Developing Mouse Ovary as a New Paradigm in Growth Regulation
Endocrinology,
January 1, 2001;
142(1):
381 - 389.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|